SARMs vs Steroids vs Peptides: Family Differences

Why these families need to be separated before any decision

Most comparison articles online rank these compounds on a single axis — 'stronger or weaker', 'safer or riskier'. That linear view is misleading. An anabolic steroid, a SARM and a recovery peptide are not substitutes for each other: they solve different problems, act on different biological targets, and expose users to different risks. Confusing them leads to protocol errors — a beginner who picks HGH thinking it is 'softer than testosterone' is making a category mistake; an athlete who stacks SARMs assuming there will be no suppression is making the same kind of error.

A useful read sits on four axes: the biological target (which receptor or hormonal pathway), the HPTA suppression (whether endogenous testosterone production gets shut down), the time-to-effect (a few days, a few weeks, several months), and the monitoring required (which bloods, how often). Those four axes structure the table below.

Anabolic steroids: the reference family

Anabolic-androgenic steroids (AAS) are synthetic derivatives of testosterone that bind to the androgen receptor found in most tissues of the body ^[1]. That ubiquity explains both their effectiveness (muscle gain, strength, recovery) and their side-effect profile (skin, hair, prostate, cardiovascular, liver for orals, HPTA suppression). It is also the most thoroughly documented family — several decades of clinical, medical and community track record.

Structural characteristics

• Total and systematic HPTA suppression. Every cycle shuts down endogenous testosterone production and stops spermatogenesis ^[8]. PCT is non-negotiable.
• Aromatization for certain compounds. Testosterone, Dianabol and nandrolone aromatize to estradiol — hence the need for estradiol monitoring and sometimes an aromatase inhibitor.
• Liver toxicity specific to 17α-alkylated orals. Oral compounds (Dianabol, Winstrol, Anadrol, Anavar) raise AST/ALT and need short windows — see the liver health and orals guide.
• Degraded cardiovascular profile. HDL drops, hematocrit climbs, sometimes blood pressure rises. The heart health on cycle guide unpacks the implications.

Who is this family built for? Users who accept the side-effect profile and the PCT requirement, who have 3 to 5 years of structured training behind them, who put the money down for monitoring (bloods before/during/after), and who start with a simple cycle — generally testosterone only. The first steroid cycle guide develops those prerequisites.

SARMs: the promise of selectivity

SARMs (Selective Androgen Receptor Modulators) are non-steroidal molecules that also bind to the androgen receptor, but with variable affinity across tissues. The original idea: act preferentially on muscle and bone, and little on skin, hair or prostate. The anabolic/androgenic ratio of the main SARMs is indeed much more favorable than testosterone — on paper.

Reality is more nuanced. Tissue selectivity is never total ^[2], and HPTA suppression is real — moderate for Ostarine (MK-2866) at contained doses, marked for LGD-4033 (Ligandrol) and RAD-140 (Testolone) at effective doses. PCT is therefore required for LGD and RAD; for Ostarine, a mini-PCT (Nolvadex 20 mg over 4 weeks) is often enough. The SARMs PCT guide walks through that decision.

The MK-677 and Cardarine special cases

Two molecules get regularly filed under 'SARMs' even though they are not pharmacologically: MK-677 (Ibutamoren) is a growth hormone secretagogue — it does not touch the androgen receptor and does not suppress the HPTA. Cardarine (GW-501516) is a PPARδ agonist — it acts on cellular metabolism and endurance, with no relation to androgens. Classing them as SARMs is a vendor convention, not a pharmacological fact.

Product quality is this family's Achilles heel: the SARMs market is less regulated than the historic underground steroid labs, and underdosing, substitution by prohormones and contamination are routinely documented by the few independent analysis labs that look. A SARMs cycle with no bloods (including LH/FSH) cannot tell you whether the product was active or not.

Peptides: one word, several distinct categories

The word 'peptide' is a chemical category (short chains of amino acids), not a pharmacological one: the molecules that fall under it have completely different biological targets. In bodybuilding, two main groups are useful.

Growth hormone peptides

The GHRP (Ipamorelin, GHRP-2, GHRP-6) and the GHRH (CJC-1295, Mod GRF 1-29). They stimulate pulsatile growth hormone release from the pituitary. The GHRP + GHRH stack amplifies the natural pulse without disconnecting the axis — IGF-1 climbs, endogenous GH stays regulated ^[4]. No HPTA suppression, no PCT. The GHRP/GHRH guide develops the protocol and injection timing.

Tissue repair peptides

Essentially BPC-157 and TB-500. They have no hormonal action — they work on the tissue-repair pathways (tendons, ligaments, muscles, mucosa). No suppression, no PCT, a short side-effect profile. The recovery peptides guide explains the BPC + TB stack and the oncology precaution (these peptides stimulate cellular growth and are contraindicated for users with a cancer history).

The full panorama is in the peptides for bodybuilding guide — including the realistic expectations: peptides do not replace a steroid cycle for raw mass, but they open a complementary use (recovery, sleep quality, healing) that is their own.

HGH: its own category

Recombinant somatropin (HGH) is neither a steroid nor a peptide in the bodybuilding sense: it is human growth hormone itself, produced by genetic engineering and injected subQ. It acts through the GH receptor and then through hepatic IGF-1 production.

• IU dosing, not mg. Typical ranges: 2 to 6 IU/day for anti-aging or recomp use; 6 to 12 IU/day for advanced users. Short half-life (3 to 4 h) but very slow biological effects.
• Long time-to-effect. 3 to 6 months to see structural benefits (lean mass, skin quality, joints). No '4 weeks in' satisfaction.
• Insulin resistance. GH raises fasting glucose and can induce insulin resistance — glucose monitoring (HbA1c, fasting glucose) is useful, particularly in predisposed users.
• Cost and source quality. Authentic pharmaceutical HGH (Pfizer Genotropin, Lilly Humatrope, Novo Nordisk Norditropin) costs a fortune; the underground market is saturated with underdosed or counterfeit products. An 'HGH cycle' with no certainty about source is largely a lost investment.

HGH does not suppress the HPTA and needs no PCT. It does inhibit endogenous GH production during use, which restarts fairly quickly after you stop ^[5]. The HGH guide develops the protocol, the bloods to plan, and the precautions.

Who each family is built for

What follows is not a use recommendation — it is a framing tool to position each family in context. The choice of whether to use any of them is personal, and remains subject to the legal framework of the country of residence and to the advice of a healthcare professional who has been informed.

Monitoring changes by family

Too many users assume blood work 'is for steroids'. It is not. Each family calls for a specific monitoring protocol — different, but real ^[7].

The global approach and standard windows are detailed in the blood work on cycle guide and in the blood test schedule.

The most frequent confusions

• "SARMs do not need a PCT." False for LGD-4033 and RAD-140 at effective doses. Partially true for Ostarine at contained doses. See the SARMs PCT guide.
• "HGH is softer than a cycle." HGH has a different risk profile (insulin resistance, carpal tunnel syndrome, internal tissue hypertrophy at high doses) — neither softer nor harsher, just different.
• "BPC-157 and TB-500 are supplements." No: they are injectable peptides. The short side-effect profile does not waive the oncology precaution (stimulated cellular growth).
• "Ipamorelin replaces a cycle." No: it amplifies the endogenous GH pulse, producing modest recovery and lipolysis effects, unrelated to the muscle gains of a cycle.
• "Cardarine + Ostarine = risk-free cutting." The animal carcinogenic controversy on Cardarine is unresolved. Short cycles only, no continuous use.

The antidote to these confusions is the same as for the rest: frame the decision on real pharmacology (not vendor marketing), accept measurement (bloods before/during/after), and move one product at a time. The doctrine is summarized in the harm reduction on cycle guide.

Frequently asked questions